H.C. Wainwright Sticks to Its Hold Rating for OncoMed Pharma (OMED)


In a report released today, Edward White from H.C. Wainwright maintained a Hold rating on OncoMed Pharma (NASDAQ: OMED), with a price target of $3. The company’s shares opened today at $2.10, close to its 52-week low of $1.74.

According to TipRanks.com, White is a top 100 analyst with an average return of 26.9% and a 56.2% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Synthetic Biologics Inc.

Currently, the analyst consensus on OncoMed Pharma is a Hold with an average price target of $3.

See today’s analyst top recommended stocks >>

The company has a one-year high of $5.56 and a one-year low of $1.74. Currently, OncoMed Pharma has an average volume of 64.57K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

OncoMed Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on discovering and developing novel therapeutics for cancer’s growth, resistance, recurrence and metastasis. The company was founded by Michael F. Clarke and Max Wicha in August 2004 and is headquartered in Redwood City, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts